Cardiovascular disease risk characteristics of the main polycystic ovary syndrome phenotypes

Dilbaz, Berna; Özkaya, Enis; Cinar, Mehmet; Cakir, Evrim; Dilbaz, Serdar
June 2011
Endocrine (1355008X);Jun2011, Vol. 39 Issue 3, p272
Academic Journal
The aim of this article was to evaluate the clinical, endocrine, and cardiovascular disease risk profile differences among main polycystic ovary syndrome (PCOS) phenotypes. One hundred and thirty-nine consecutive women were included in the study. Body mass index (BMI), serum follicle stimulating hormone (FSH), luteinizing hormone (LH), progesterone, estradiol, testosterone, dehydroepiandrosterone sulfate, fasting glucose, low density lipoprotein (LDL-C), total cholesterol, high density lipoprotein (HDL-C) high sensitive CRP, c-peptide, insulin, insulin sensitivity and carotid intima thickness were compared among different phenotype groups of PCOS: Group 1-PCO (polycystic ovaries)-anovulation ( n = 34), Group 2-Hyperandrogenemia (HA)-anovulation ( n = 30), Group 3-HA-PCO ( n = 32), and Group 4-HA-PCO-anovulation ( n = 43). Statistically significant differences among the different phenotype groups in terms of waist hip ratio, total cholesterol, LH, estradiol, fasting glucose, progesterone, free testosterone, and carotid intima media thickness were observed. The lowest mean CIMT was observed in Group 3, and the highest fasting glucose levels were in Group 4, while the lowest mean free testesterone was measured in Group 1. BMI, LDL-C, and total cholesterol showed significant positive correlations with CIMT ( r = 0.411, P = 0.001; r = 0.258, P = 0.006; r = 0.199, P = 0.033). The lowest LDL-C, total cholesterol, and BMI were found in Group 3, but differences were not statistically significant. High-sensitive CRP levels were similar among the groups ( P = 0.103). Group 3 PCOS with PCO and hyperandrogenemia phenotype has lower cardiovascular disease risk compared to other phenotypes.


Related Articles

  • Comparison of GnRH agonists and antagonists in the outcome of IVF/ICSI in women with polycystic ovary syndrome. Zeinalzadeh, M.; Norani, N.; Esmaeilzadeh, S.; Yousefniapasha, Y.; Firoozpour, M.; Khafri, S. // Iranian Journal of Reproductive Medicine;Jun2014 Supplement, Vol. 12, p58 

    Introduction: To compare the outcome of using gonadotropin-releasing hormone (GnRH) antagonists versus agonists in women with polycystic ovary syndrome (PCOS) who underwent controlled ovarian hyper stimulation (COH) for assisted reproductive techniques (ART). Materials and Methods: A total of...

  • The Use of a Combined Regimen of GnRH Agonist Plus a Low-Dose Oral Contraceptive Improves the... Genazzani, Alessandro D.; Battaglia, Cesare // Journal of Assisted Reproduction & Genetics;May2000, Vol. 17 Issue 5, p269 

    Studies the efficacy of the gonadotropin-releasing hormone-analogue (GnRH-a) and oral contraceptive (OC) in restoring gonadotropin discharge in women with polycystic ovary disease (PCOD). Correlation between treatment and levels of gonadotropin; Monitoring of luteinizing hormone gonadotropin...

  • Fixed versus Flexible Gonadotropin Releasing Hormone Antagonist Protocol in Controlled Ovarian Stimulation for Invitro Fertilization in Women with Polycystic Ovary Syndrome. Rashidi, Batool Hossein; Lak, Tahereh Behrouzi; Tehrani, Ensiyeh Shahrokh; Tanha, Fatemeh Davari // Journal of Family & Reproductive Health;Sep2015, Vol. 9 Issue 3, p141 

    Objective: This study was conducted to compare the results of fixed versus flexible GnRH antagonist protocols in controlled ovarian stimulation for Intra Cytoplasmic Sperm Injection (ICSI) in patients with PCOS. Materials and methods: A randomized clinical trial was performed on 100 PCOS women,...

  • Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: a prospective randomized study. Jiann-Loung Hwang; Kok-Min Seow; Yu-Hung Lin; Lee-Wen Huang; Bih-Chwen Hsieh; Yieh-Loong Tsai; Gong-Jhe Wu; Shih-Chia Huang; Chin-Yu Chen; Pei-Hsin Chen; Chii-Ruey Tzeng // Human Reproduction;Sep2004, Vol. 19 Issue 9, p1993 

    BACKGROUND: Patients with polycystic ovary syndrome (PCOS) may need a longer period of pituitary downregulation to suppress the elevated serum LH and androgen levels effectively during IVF treatment using the GnRH agonist long protocol. We proposed a stimulation protocol incorporating Diane-35...

  • Gonadotropin-releasing hormone: cardiovascular risk.  // WHO Drug Information;2011, Vol. 25 Issue 4, p359 

    No abstract available.

  • GnRH agonists carry considerable cardiovascular risks.  // Reactions Weekly;1/30/2010, Issue 1286, p4 

    The article discusses research on the association of gonadotropin-releasing hormone (GnRH) agonists and cardiovascular risks, that references a study by N. L. Keating and colleages published in the December 7, 2009 issue of the "Journal of the National Cancer Institute."

  • ART, clinical: GnRH agonist/antagonist.  // Human Reproduction;Jul2007 Supplement 1, Vol. 22, pi120 

    The article presents abstracts on the use of gonadotropin-releasing hormone (GnRH) agonists and antagonists in assisted reproductive technology (ART), including the administration of gonadoliberine analogues (GnRH-a) to patients with Hodgkin lymphoma (HL) during chemotherapy and prevention of...

  • Optimal usage of the GnRH antagonists: a review of the literature. Copperman, Alan B.; Benadiva, Claudio // Reproductive Biology & Endocrinology;2013, Vol. 11 Issue 1, p1 

    Gonadotropin-releasing hormone (GnRH) antagonists, which became commercially available from 1999, have been used for the prevention of premature luteinizing hormone (LH) surges in controlled ovarian stimulation for in vitro fertilization or intracytoplasmic sperm injection. This review focuses...

  • Ovarian stimulation in women with high and low body mass index: GnRH agonist versus GnRH antagonist. Kumbak, Banu; Akbas, Hande; Sahin, Levent; Karlikaya, Guvenc; Karagozoglu, Hale; Kahraman, Semra // Reproductive BioMedicine Online (Reproductive Healthcare Limited;Mar2010, Vol. 20 Issue 3, p314 

    This study evaluated women with a high body mass index (BMI) (>40 kg/m²) and low BMI (<18 kg/m²) undergoing assisted reproduction treatment and determined whether the type of gonadotrophin-releasing hormone (GnRH) analogue used has an impact on cycle parameters and outcome. The study...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics